Furthermore, miR-34a regulates lipid-metabolism gene expression, specifically targeting liver peroxisome proliferation-activator receptor α (PPARα) and inhibiting very low-density lipoprotein secretion, while promoting hepatic steatosis and hypolipidemic effects in a HNF4-dependent manner [42]. The gene discussed is PPARA; the disease is fatty liver disease.